Acumen Pharmaceuticals Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 61

Employees

  • Stock Symbol
  • ABOS

Stock Symbol

  • Share Price
  • $0.21
  • (As of Friday Closing)

Acumen Pharmaceuticals General Information

Description

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1210-1220 Washington Street
  • Suite 210
  • Newton, MA 02465
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 1210-1220 Washington Street
  • Suite 210
  • Newton, MA 02465
  • United States
+1 (617)

Acumen Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Acumen Pharmaceuticals Stock Performance

As of 13-Nov-2026, Acumen Pharmaceuticals’s stock price is $0.21. Its current market cap is $15.5M with 72.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.21 $0.22 $0.19 - $3.60 $15.5M 72.3M 2.53M -$1.55

Acumen Pharmaceuticals Financials Summary

As of 30-Sep-2026, Acumen Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 81,993 32,037 (68,538) 6,944
Revenue 0 0 0 0
EBITDA (103,838) (124,374) (112,400) (62,397)
Net Income (103,962) (121,335) (102,329) (52,371)
Total Assets 85,565 122,833 238,992 310,125
Total Debt 26,311 31,311 28,732 28,487
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Acumen Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Acumen Pharmaceuticals‘s full profile, request access.

Request a free trial

Acumen Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Acumen Pharmaceuticals‘s full profile, request access.

Request a free trial

Acumen Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach t
Drug Discovery
Newton, MA
61 As of 2026

Gothenburg, Sweden
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Acumen Pharmaceuticals Competitors (21)

One of Acumen Pharmaceuticals’s 21 competitors is Alzinova, a Corporation company based in Gothenburg, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alzinova Corporation Gothenburg, Sweden
ProMIS Neurosciences Corporation Toronto, Canada
Prothena Corporation Dublin, Ireland
LeonaBio Formerly VC-backed Bothell, WA
Denali Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 21 competitors. Get the full list »

Acumen Pharmaceuticals Patents

Acumen Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026164979-A1 Anti-oligomeric amyloid beta antibody variant and methods of use thereof Pending 28-Jan-2025
AU-2013355359-A1 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 Active 04-Dec-2012
AU-2013355359-B2 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 Active 04-Dec-2012
CA-2891627-A1 Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 Active 04-Dec-2012
CA-2891627-C Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 Active 04-Dec-2012 A61K39/3955
To view Acumen Pharmaceuticals’s complete patent history, request access »

Acumen Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Acumen Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Acumen Pharmaceuticals‘s full profile, request access.

Request a free trial

Acumen Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.94 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Acumen Pharmaceuticals’s complete esg history, request access »

Acumen Pharmaceuticals FAQs

  • When was Acumen Pharmaceuticals founded?

    Acumen Pharmaceuticals was founded in 1996.

  • Where is Acumen Pharmaceuticals headquartered?

    Acumen Pharmaceuticals is headquartered in Newton, MA.

  • What is the size of Acumen Pharmaceuticals?

    Acumen Pharmaceuticals has 61 total employees.

  • What industry is Acumen Pharmaceuticals in?

    Acumen Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Acumen Pharmaceuticals a private or public company?

    Acumen Pharmaceuticals is a Public company.

  • What is Acumen Pharmaceuticals’s stock symbol?

    The ticker symbol for Acumen Pharmaceuticals is ABOS.

  • What is the current stock price of Acumen Pharmaceuticals?

    As of 13-Nov-2026 the stock price of Acumen Pharmaceuticals is $0.21.

  • What is the current market cap of Acumen Pharmaceuticals?

    The current market capitalization of Acumen Pharmaceuticals is $15.5M.

  • Who are Acumen Pharmaceuticals’s competitors?

    Alzinova, ProMIS Neurosciences, Prothena, LeonaBio, and Denali Therapeutics are some of the 21 competitors of Acumen Pharmaceuticals.

  • What is Acumen Pharmaceuticals’s annual earnings per share (EPS)?

    Acumen Pharmaceuticals’s EPS for 12 months was -$1.55.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process